Brown Capital Management LLC Sells 254,648 Shares of CryoPort, Inc. $CYRX

Brown Capital Management LLC trimmed its position in shares of CryoPort, Inc. (NASDAQ:CYRX) by 6.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,798,962 shares of the company’s stock after selling 254,648 shares during the quarter. Brown Capital Management LLC owned 7.58% of CryoPort worth $28,340,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Nisa Investment Advisors LLC increased its stake in CryoPort by 299.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of CryoPort during the second quarter valued at about $75,000. Avanza Fonder AB increased its position in shares of CryoPort by 31.4% during the second quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock worth $81,000 after acquiring an additional 2,601 shares in the last quarter. PharVision Advisers LLC acquired a new stake in shares of CryoPort in the 2nd quarter worth about $82,000. Finally, Savant Capital LLC bought a new position in CryoPort in the 2nd quarter valued at about $93,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insider Transactions at CryoPort

In related news, Director Robert J. Hariri sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $9.71, for a total transaction of $242,750.00. Following the completion of the sale, the director owned 51,275 shares in the company, valued at approximately $497,880.25. This trade represents a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on CYRX. UBS Group boosted their price objective on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday, November 5th. BTIG Research upped their price target on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Weiss Ratings reissued a “sell (d)” rating on shares of CryoPort in a research report on Monday, November 24th. Finally, Needham & Company LLC lifted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $12.83.

CryoPort Stock Performance

Shares of CryoPort stock opened at $9.88 on Friday. The business’s fifty day simple moving average is $9.39 and its 200 day simple moving average is $8.34. The firm has a market capitalization of $494.69 million, a P/E ratio of 8.44 and a beta of 1.51. CryoPort, Inc. has a 12 month low of $4.58 and a 12 month high of $11.44. The company has a current ratio of 15.77, a quick ratio of 15.01 and a debt-to-equity ratio of 0.40.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.The firm had revenue of $44.23 million during the quarter, compared to the consensus estimate of $41.22 million. As a group, analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current year.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.